We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Eye Care

Journal Scan / Research · May 05, 2020

Abicipar in Neovascular Age‐Related Macular Degeneration

Ophthalmology: Journal of the AAO


Additional Info

Disclosure statements are available on the authors' profiles:

Ophthalmology: Journal of the AAO
Efficacy and Safety of Abicipar in Neovascular Age‐Related Macular Degeneration: 52-Week Results of Phase 3 Randomized Controlled Study
Ophthalmology 2020 Apr 09;[EPub Ahead of Print], D Kunimoto, YH Yoon, CC Wykoff, A Chang, RN Khurana, RK Maturi, H Agostini, E Souied, DR Chow, AJ Lotery, M Ohji, F Bandello, R Belfort Jr, X-Y Li, J Jiao, G Le, W Schmidt, Y Hashad, CEDAR and SEQUOIA Study Groups

Further Reading